Exploring Selection + Sequencing: A Multidisciplinary Tumor Board Discussion on Treatment Options for Patients With Advanced HCC

Faculty

Andrew X. Zhu, MD, PhD

Director, Jiahui International Cancer Center
Shanghai, China 
Director Emeritus, Liver Cancer Program
Massachusetts General Hospital Cancer Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Catherine Frenette, MD, FAST, AGAF, FAASLD

Medical Director, Liver Transplantation
Scripps Center for Organ Transplantation
Scripps Green Hospital
Director, Liver and Hepatocellular Cancer Program
Scripps MD Anderson Cancer Center
La Jolla, California

Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN

Nurse Practitioner, Medical Oncology
Abramson Cancer Center
Penn Presbyterian Medical Center
Advanced Senior Lecturer B
Biobehavioral and Health Sciences Division
Adult Oncology Specialty Minor/Post Masters Certificate
University of Pennsylvania School of Nursing
Philadelphia, Pennsylvania

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Evaluate and apply emerging clinical data, evolving strategies, and treatment guidelines for patients with advanced HCC

Using a clinical case, understand the role of, and integrate the use of, systemic therapies including tyrosine kinase inhibitors and immunotherapies in the treatment algorithm for advanced HCC while considering clinical and tumor characteristics

Evaluate strategies for clinical management of symptoms in patients receiving treatment for advanced HCC

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

• Planners (Forefront Collaborative): Valerie Siclari, PhD; Christine Tebben
• Planner Faculty: Paul Oakes
• Faculty Presenter: Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

• Faculty Presenter: Andrew X. Zhu, MD, PhD
  • Consultant: Bayer, Eisai, Exelixis, Lilly, Merck, Roche, Sanofi
• Faculty Presenter: Catherine Frenette, MD, FAST, AGAF, FAASLD
  • Consultant: Bayer, Conatus, Genentech, Merck
  • Speakers Bureau: AbbVie, Bayer, Bristol Myers Squibb, Eisai, Exelixis, Genentech, Gilead, Intercept, Mallinckrodt, Salix
  • Advisory Board: Bayer, Eisai, Exelixis, Genentech, Gilead, Merck, Wako/Fujifilm
  • Contracted Research: Bayer, Conatus, Exelixis, Genentech, Merck

Activity Information

Target Audience
This activity will engage a multidisciplinary target audience that will include medical oncologists, hepatologists, gastroenterologists, interventional radiologists, oncology nurse practitioners, oncology nurses, and other healthcare professionals such as primary care physicians and pharmacists involved in the care of patients with advanced HCC. 

Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Bayer Healthcare Pharmaceuticals Inc., and Exelixis, Inc.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Provider
This activity is provided by Forefront Collaborative.

Commercial Support
This educational activity is jointly supported by a medical education grant from Bayer Healthcare Pharmaceuticals Inc. and Exelixis, Inc.